Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.84 Insider Own7.52% Shs Outstand38.64M Perf Week-11.23%
Market Cap63.10M Forward P/E- EPS next Y-2.16 Insider Trans0.00% Shs Float36.02M Perf Month-31.06%
Income-70.79M PEG- EPS next Q-0.40 Inst Own17.36% Short Float0.02% Perf Quarter-32.78%
Sales0.34M P/S185.59 EPS this Y-4.19% Inst Trans54.42% Short Ratio0.25 Perf Half Y-50.31%
Book/sh4.40 P/B0.37 EPS next Y-8.38% ROA-30.69% Short Interest0.01M Perf Year-29.57%
Cash/sh3.34 P/C0.49 EPS next 5Y- ROE-34.95% 52W Range1.64 - 5.10 Perf YTD-56.10%
Dividend Est.- P/FCF- EPS past 5Y- ROI-38.74% 52W High-68.24% Beta-0.48
Dividend TTM- Quick Ratio11.15 Sales past 5Y4086.64% Gross Margin-1679.40% 52W Low-1.22% ATR (14)0.18
Dividend Ex-Date- Current Ratio11.15 EPS Y/Y TTM-346.15% Oper. Margin-25235.49% RSI (14)32.46 Volatility8.65% 8.52%
Employees130 Debt/Eq0.07 Sales Y/Y TTM-98.88% Profit Margin-21127.41% Recom1.50 Target Price5.80
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q17.28% Payout- Rel Volume0.81 Prev Close1.69
Sales Surprise- EPS Surprise26.47% Sales Q/Q-100.00% EarningsMay 13 BMO Avg Volume22.95K Price1.62
SMA20-19.75% SMA50-30.46% SMA200-42.18% Trades Volume18,621 Change-4.14%
Date Action Analyst Rating Change Price Target Change
May-25-21Initiated William Blair Outperform
May-25-21Initiated Morgan Stanley Overweight $22
May-25-21Initiated Jefferies Buy $28
May-24-21Initiated H.C. Wainwright Buy $25
Jun-12-24 04:01PM
Jun-06-24 11:15AM
May-22-24 08:00AM
May-13-24 01:53PM
07:00AM Loading…
May-01-24 07:00AM
Apr-18-24 04:10PM
Mar-20-24 01:52PM
Jan-05-24 04:01PM
Dec-21-23 07:31AM
Nov-09-23 04:24PM
Nov-06-23 09:05AM
06:23AM Loading…
Oct-04-23 06:23AM
Sep-13-23 08:00AM
Aug-10-23 08:00AM
Aug-09-23 07:37AM
Jul-19-23 08:34PM
Jun-29-23 07:11AM
Jun-21-23 09:03AM
Jun-12-23 07:30AM
May-19-23 06:04AM
May-12-23 08:00AM
May-05-23 07:33AM
Apr-17-23 09:00AM
Apr-05-23 01:40PM
08:00AM Loading…
Mar-28-23 08:00AM
Mar-24-23 08:06AM
Mar-20-23 12:44PM
Mar-16-23 06:47AM
Mar-01-23 06:01AM
Jan-30-23 08:00AM
Jan-13-23 05:24AM
Nov-21-22 10:31AM
Nov-13-22 07:29AM
Nov-10-22 04:30PM
Nov-09-22 08:00AM
Nov-07-22 08:00AM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-27-22 07:00AM
Oct-06-22 11:45AM
Oct-03-22 04:30PM
Sep-20-22 04:30PM
Sep-07-22 04:01PM
Aug-15-22 06:14AM
Aug-11-22 09:14AM
Aug-09-22 04:15PM
Jul-07-22 04:15PM
Jul-03-22 10:08AM
Jun-22-22 01:34PM
Jun-06-22 04:15PM
May-20-22 11:30AM
May-19-22 06:32AM
May-11-22 04:15PM
Apr-29-22 10:30AM
Apr-06-22 04:15PM
Mar-25-22 07:15AM
Mar-07-22 08:00AM
Jan-21-22 03:41AM
Jan-18-22 03:00AM
Jan-13-22 04:34PM
Jan-10-22 10:00AM
Dec-13-21 04:05PM
Dec-07-21 08:00AM
Nov-24-21 09:20AM
Nov-12-21 08:00AM
Nov-10-21 08:00AM
Nov-04-21 04:00AM
Oct-28-21 01:23PM
Oct-18-21 08:00AM
Oct-13-21 08:00AM
Sep-13-21 12:38PM
Sep-09-21 08:00AM
Aug-12-21 08:00AM
Jul-30-21 10:00AM
Jul-08-21 08:00AM
Jul-06-21 10:19AM
Jun-20-21 08:00PM
Jun-14-21 05:49PM
Jun-01-21 08:00AM
May-06-21 04:32PM
May-04-21 05:07PM
Apr-29-21 06:49PM
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scheeren JosephDirectorJun 26 '23Buy2.4410,00024,40023,000Jun 28 07:52 AM